Dr. Kennen MacKay, Managing Director and Co-Head of Biotechnology Research for RBC Capital Markets, joins Janet Engels, Head of the Portfolio Advisory Group – U.S., to talk about where things stand with COVID-19. They zero in on the data on the number of cases, and discuss how close we are to a vaccine as well as the impact of the race to find effective treatments, now and in the future. Janet asks the question on all our minds: “When will we be back to normal?”

Listen here (approximately 20-minute duration).

If you have any questions or need further guidance, please do not hesitate to contact me.